The use of chondroitin sulfate in prolonging survival of adult skin allografts.
D000014:Abnormalities, Drug-Induced; D000367:Age Factors; D000818:Animals; D001485:Basement Membrane; D002807:Chondroitin / Q000032:analysis / Q000494:pharmacology*; D005260:Female; D005333:Fetus / Q000276:immunology; D006084:Graft Rejection / Q000187:drug effects; D006470:Hemorrhage / Q000473:pathology; D006493:Heparin / Q000494:pharmacology; D006648:Histocompatibility; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D010920:Placenta / Q000032:analysis / Q000276:immunology*; D011247:Pregnancy; D012867:Skin / Q000473:pathology; D016038:Skin Transplantation; D013431:Sulfates; D013997:Time Factors; D014181:Transplantation Immunology / Q000187:drug effects*; D014184:Transplantation, Homologous; D014327:Trophoblasts / Q000032:analysis
D007166:Immunosuppressive Agents; D013431:Sulfates; D006493:Heparin; D002807:Chondroitin